APC
CRBP icon

Aspire Private Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Aspire Private Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7
Closed -$1K – 284
2019
Q4 		$1K Hold
7
– – ﹤0.01% 419
2019
Q3 		$1K Hold
7
– – ﹤0.01% 394
2019
Q2 		$1K Hold
7
– – ﹤0.01% 434
2019
Q1 		$1K Buy
+7
New +$1.54K ﹤0.01% 487

Other funds holding CRBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aspire Private Capital's CRBP Position: Q1 2020 in Review

Aspire Private Capital sold out of Corbus Pharmaceuticals (CRBP) in Q1 2020, closing a stake of 7 shares — an estimated $1K sold.

Aspire Private Capital first reported a position in CRBP in Q1 2019 and held it in 4 quarters. The position peaked at $1K in Q4 2019. 111 funds tracked by Wall St. Rank hold CRBP as of Q1 2020.

  • Aspire Private Capital reported no remaining Corbus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Aspire Private Capital sold 7 Corbus Pharmaceuticals shares in Q1 2020, an estimated $1K.
  • Aspire Private Capital first reported a position in Corbus Pharmaceuticals in Q1 2019 and held it in 4 quarters.
  • Aspire Private Capital's Corbus Pharmaceuticals position peaked at $1K in Q4 2019.
  • 111 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2020.

Based on Aspire Private Capital's 13F filing for Q1 2020, filed 14 May 2020.